Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
TheFly reported on June 15 that UBS initiated coverage of JBIO with a Buy rating and a $45 price target.
Jade Biosciences Inc. (JBIO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 3,671,083 | $51,578,716 | 0.55% | |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,641,137 | $23,057,975 | 0.13% | |
| 3. | Remedium Capital Partners David Hawkins | 1,577,750 | $22,167,388 | 7.88% | |
| 4. | Avidity Partners Management David Witzke And Michael Gregory | 1,400,708 | $19,679,947 | 3.89% | |
| 5. | Samsara BioCapital Srini Akkaraju And Michael Dybbs | 968,798 | $13,611,612 | 1.32% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.40 | 6,000 | $44,400.00 | 6,000 | 2025-05-16 | Filing | |
| $1.67 | 928,110 | $1,549,943.70 | 7,893,678 | 2024-06-17 | Filing | |
| $14.00 | 500,000 | $7,000,000.00 | 2,030,691 | 2021-07-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.03 | 15,000 | $375,450.00 | 5,022 | 2024-06-14 | Filing | |
| $25.00 | 10,600 | $265,000.00 | 0 | 2024-06-14 | Filing | |
| $24.50 | 6,000 | $147,000.00 | 5,602 | 2024-06-13 | Filing | |
| $21.86 | 86 | $1,879.96 | 5,602 | 2024-05-17 | Filing | |
| $21.07 | 3,914 | $82,451.54 | 5,688 | 2024-05-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,085,423 | $99,550,194 | 0.01% | |
| 2. | 4,553,494 | $63,976,591 | 4.62% | |
| 3. | 3,501,502 | $49,196,103 | 1.17% | |
| 4. | 3,220,364 | $45,246,114 | 1.69% | |
| 5. | 3,105,669 | $43,557,008 | 0.02% |
News See All
10 Best Biotech Stocks to Buy According to Analysts
Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, rising merger activity, and renewed investor confidence.
H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue
Jade Biosciences Inc. (NASDAQ:JBIO) is one of the overlooked growth stocks to buy. On January 7, H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target.
9 Overlooked Growth Stocks to Buy
On January 12, Victoria Greene, Founding Partner and CIO at G Squared Private Wealth, joined CNBC to discuss her current market outlook, selecting 'Fundamentals' as her word of the day.
Jade Biosciences (JBIO): Analyst Lauds Entry into Market
On November 25, Clear Street analyst Kaveri Pohlman initiated coverage of Jade Biosciences, Inc. (NASDAQ:JBIO) stock with a Buy rating and $25 price target.
11 Best Micro-Cap Stocks to Invest in According to Analysts
Micro-cap companies, generally referring to publicly traded businesses with less than $300 million in market capitalization, are among the most volatile and high-risk investments in the stock market.
Hedge Fund Resource Center